Compare PACCAR Inc. Common Stock (PCAR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PACCAR Inc. Common Stock vs Repligen Corporation Common Stock — how do they compare? PACCAR Inc. Common Stock trades at $109.1 (market cap $57.14B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: PACCAR Inc. Common Stock is far larger — about 5.1× Repligen Corporation Common Stock's market cap, and PACCAR Inc. Common Stock pays a 1.29% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold PACCAR Inc. Common Stock for 6 Days and Repligen Corporation Common Stock for 0 Days on average.
| PCAR | RGEN | |
|---|---|---|
Market Cap | $57.14B | $11.31B |
Volume | 2,748,310 | 1,216,919 |
Sector | Industrials | Health |
52-Week High | $138.21 | $194.57 |
52-Week Low | $94.15 | $102.87 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $63.00B | $11.20B |
Dividend Yield | 1.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PACCAR (PCAR) trades at $107.98, down 0.14% with bearish technical signals but strong fundamentals including 9% net income margin and 12.76% ROE. Recent earnings beat expectations in Q2 2026 with $1.43 EPS versus $1.36 expected. The company maintains stable cash flows with $4.3B operating cash flow projected for 2026 and recently declared a $0.35 quarterly dividend payable December 2026.
PCAR presents a mixed outlook with Wall Street consensus price target of $134.83 suggesting 25% upside potential, though technical indicators show bearish momentum. Key risks include sector sensitivity to interest rates and industrial cyclicality, while opportunities lie in the company's strong profitability metrics and defensive non-trucking segments representing over 60% of earnings.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PACCAR Inc. Common Stock
PACCAR designs and manufactures heavy-duty trucks under brands including Peterbilt, Kenworth, and DAF. It also provides parts, financial services, and technology for commercial vehicles.
Read more on PCAR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
